Lexicon Pharmaceuticals (LXRX) to Release Earnings on Tuesday

Lexicon Pharmaceuticals (NASDAQ:LXRX) will be releasing its earnings data after the market closes on Tuesday, November 12th. Analysts expect Lexicon Pharmaceuticals to post earnings of ($0.17) per share for the quarter. Individual interested in listening to the company’s earnings conference call can do so using this link.

Lexicon Pharmaceuticals Stock Performance

NASDAQ LXRX opened at $1.27 on Friday. The company has a fifty day moving average of $1.67 and a two-hundred day moving average of $1.75. The company has a market capitalization of $312.72 million, a PE ratio of -1.63 and a beta of 1.24. Lexicon Pharmaceuticals has a 1 year low of $0.92 and a 1 year high of $3.73. The company has a debt-to-equity ratio of 0.41, a current ratio of 11.51 and a quick ratio of 11.49.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on LXRX shares. HC Wainwright restated a “buy” rating and set a $6.00 price target on shares of Lexicon Pharmaceuticals in a research note on Tuesday, November 5th. Needham & Company LLC reiterated a “hold” rating on shares of Lexicon Pharmaceuticals in a research note on Wednesday, October 30th. Finally, Leerink Partners set a $6.00 price objective on shares of Lexicon Pharmaceuticals and gave the company an “outperform” rating in a research note on Friday, October 18th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating to the company. Based on data from MarketBeat.com, Lexicon Pharmaceuticals presently has a consensus rating of “Hold” and an average target price of $6.00.

Lexicon Pharmaceuticals Company Profile

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract.